United Kingdom

People: Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

23 Jul 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gasmi, Mehdi 

Dr. Mehdi Gasmi, Ph.D. is Chief Science and Technology Officer of the Company. Dr. Gasmi has served as Senior Vice President, Pharmaceutical Development of the Company since June 2015 and Vice President, Pharmaceutical Development of the Company from November 2013 to June 2015. Dr. Gasmi leads manufacturing and quality control efforts for the Company’s gene therapy product candidates. From December 2011 to November 2013, as principal of ClinVec Solutions, LLC, Dr. Gasmi provided adeno-associated virus (AAV) and lentiviral gene therapy consulting services to various companies, including to the Company between June 2013 to October 2013. Prior to that, Dr. Gasmi oversaw production of clinical batches of recombinant AAV and lentiviral gene therapy products for both Généthon, a gene therapy company, where he served as Vice President of Biomanufacturing from July 2009 to December 2011, and for Ceregene, a gene therapy company, where Dr. Gasmi served as Senior Director, Product Development from December 2001 to June 2009. Dr. Gasmi obtained his M.S. and his Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France. He is a member of the American Society of Gene and Cell Therapy.

Basic Compensation

Total Annual Compensation, USD 517,996
Restricted Stock Award, USD 337,500
Long-Term Incentive Plans, USD --
All Other, USD 512,958
Fiscal Year Total, USD 1,368,450

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --